Back to News
investment

POET Technologies: Great Technology, Terrible Investment

Seeking Alpha
Loading...
4 min read
0 likes
⚡ Quantum Brief
The company’s stock surged on AI hype and a Lumilens deal but remains overvalued, with analysts rating it a "Sell" due to minimal revenue and early-stage commercialization risks. Only a $50 million initial Lumilens order is confirmed, with large-scale shipments delayed until 2027, leaving near-term revenue growth uncertain and execution risks high. Past partnerships frequently failed to materialize, and recent disputes with Marvell/Celestial AI raise concerns about operational reliability and trust in delivering on contracts. First-quarter 2026 revenue hit just $0.5 million, with a $12 million net loss and negative cash flow, contradicting market optimism about its AI infrastructure potential. Valuation models suggest a 12.5% downside, as current pricing overestimates earnings power, ignoring the gap between hype and the company’s unproven commercialization timeline.
POET Technologies: Great Technology, Terrible Investment

Summarize this article with:

Bears of Wall Street9.8K FollowersFollow5ShareSavePlay(14min)Comments(2)SummaryPOET Technologies is rated Sell due to a disconnect between market optimism and its minimal current revenues and early commercialization stage.POET's recent Lumilens deal offers potential upside, but only the initial $50 million order is confirmed, with large-scale shipments not expected until 2027.Execution risks remain high, as past partnerships and orders have often failed to materialize, and recent events with Marvell/Celestial AI highlight trust and operational challenges.My valuation model suggests a 12.5% downside to intrinsic value, as the current price overstates POET's near-term earnings power and commercialization progress.POET Technologies (POET) has gained significant traction in the last few weeks. First, the stock experienced a major rally amid the AI-related hype, then collapsed by nearly 50%, and finally appreciated again thanks to the major deal with Lumilens. For many investors, POET now looks like a potential hidden gem in the world of photonics. There’s this thinking that the company is on the verge of mass commercialization of its products, and it can also benefit from the growth of AI data centers. The market has increasingly started to forecast a scenario in which optical interconnects will become one of the main bottlenecks for AI. This could result in the company’s technology becoming a critical component of the AI infrastructure. The problem is that there is still a huge gap between the current market narrative and reality. In our opinion, the market today looks at POET more as a future winner of AI optical networking than as an early company with minimal revenues, the absence of large-scale commercialization, and significant execution risks. That is why we believe that the current optimism looks premature, and the shares remain vulnerable to a significant downside.

The Revenue Is Almost Non-Existent The best way to understand the POET’s current state of affairs is to just look at its numbers. In the first quarter of 2026, the company showed a revenue of only about $0.5 million, which exceeded market expectations. However, this still looks extremely modest for a company that’s being treated as one of the potential beneficiaries of the AI revolution. At the same time, the business remains unprofitable. In the recent quarter, the GAAP EPS was -$0.08, while the net loss was over $12 million. Although the operating cash flow improved slightly, it is still negative and was around -$8.8 million. And thisThis article was written byBears of Wall Street9.8K FollowersFollowBears of Wall Street is a community of asset managers and traders who take a pragmatic approach to valuing companies. Bears of Wall Street provide unique research with a bearish sentiment on overvalued or weak companies with declining businesses and poor growth perspectives - companies whose likely depreciation can be capitalized on.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Read Original

Tags

quantum-commercialization
partnership

Source Information

Source: Seeking Alpha